NephrologyNow The Ultimate Guide to Kidney Disease Research

This review summarizes results of the landmark ESCAPE trial, which has shown that lowering the blood pressure target to below the 50th percentile slows pediatric chronic kidney disease progression.
document.getElementById(“post-1366-blankimage”).onload();

This review of prehypertension emphasizes the importance of diagnosing this entity early as a view to preventing cardiovascular outcomes in the population as a whole and not just those patients at high-risk.
document.getElementById(“post-1324-blankimage”).onload();

This article reviews the evidence relating dietary sodium and health.  As well, it details public health strategies to reduce population dietary salt intake.
document.getElementById(“post-1260-blankimage”).onload();

This randomized controlled trial confirms the long-term renoprotective effect of intensified blood-pressure control among children treated with high dose angiotensin-converting-enzyme (ACE) inhibitor.
document.getElementById(“post-1254-blankimage”).onload();

It has long been recognized from epidemiologic studies that cardiovascular risk increases at blood pressures far below the current hypertension treatment target of 140/90. This open-label, blinded endpoint study randomized patients with uncontrolled hypertension to a systolic BP target of <130 mm Hg or <140 mm Hg. They showed a reduction in both the primary [...]

In the meta-analysis, no reduction in morbidity or mortality benefit was found when hypertensive patients are targeted to a lower target of ≤ 135/85 mmHg as compared to a BP targets of ≤ 140-160/ 90-100 mmHg. Of note, no trials comparing different systolic BP targets were included in the analysis. Nephrology Now readers will likely be [...]

This trial using a PROBE design compared add-on therapy with an ARB as compared to alternative antihypertensive agents in Japanese patients with uncontrolled hypertension. A reduction in hard clinical endpoints was observed in the Valsartan add-on group.
document.getElementById(“post-1193-blankimage”).onload();

This insightful opinion piece discusses the unfortunate burden of poor blood pressure control despite the availability and accessibility of excellent treatment.
document.getElementById(“post-1147-blankimage”).onload();

Hypertension is common post-renal transplant and is associated with an
increased risk of graft loss and death. This meta-analysis found the
strongest evidence for calcium-channel blockers in reducing graft loss and
improving GFR. ACE-inhibitors did not reduce the incidence of graft loss and
were associated with a lower GFR, but did reduce proteinuria.
document.getElementById(“post-1062-blankimage”).onload();

This pre-specified subgroup analysis of the TRANSCEND study failed to show any significant benefit on renal outcomes between the intervention arm (using telmisartan) and placebo arm. This was not a study of chronic kidney disease patients, but rather examined patients with cardiovascular disease or diabetes, but without macroalbuminuria or heart failure.
document.getElementById(“post-899-blankimage”).onload();

document.getElementById(“post-790-blankimage”).onload();

document.getElementById(“post-720-blankimage”).onload();

document.getElementById(“post-722-blankimage”).onload();